Does Netupitant And Palonosetron Interact with Anticoagulants General Class?
CDI records a moderate classification for Netupitant And Palonosetron and Anticoagulants General Class. The stored summary is: Netupitant inhibits CYP3A4 for 6 days, increasing plasma concentrations of CYP3A4 substrates. Avoid concomitant use for one week if feasible; if unavoidable, consider dose reduction. The mechanism involves cyp3a4 inhibition by netupitant. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Netupitant And Palonosetron Class
- Serotonin-3 Receptor Antagonist
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4 inhibition by netupitant
What To Tell Your Doctor or Pharmacist
If you are taking Netupitant And Palonosetron and your doctor is considering prescribing Anticoagulants General Class (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider